(19) World Intellectual Property Organization International Bureau



TO THE ENGINEER OF COLUMN COLU

(43) International Publication Date 1 July 2004 (01.07.2004)

PCT

(10) International Publication Number WO 2004/055513 A2

(51) International Patent Classification⁷:

G01N 33/48

(21) International Application Number:

PCT/EP2003/014330

(22) International Filing Date:

16 December 2003 (16.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 02028264.6

16 December 2002 (16.12.2002)

2..8----

(71) Applicant and

(72) Inventor: SCHWARZ, Herbert [DE/DE]; Hohenbacher Str. 25, 84502 Kranzberg (DE).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): WITTMANN, Margarethe [DE/DE]; Homburger Landstr. 851, 60437 Frankfurt/Main (DE).
- (74) Agent: SCHNABEL, Jörg; Habermann, Hrschka & Schnabel, Montgelasstr. 2, 81679 Munich (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: USE OF CD137 ANTAGONISTS FOR THE TREATMENT OF TUMORS

Normal situation in early immune response:

T cell priming and expansion

T cell

Dendritic cell

vation


T cell

T cell


survival

(57) Abstract: The present invention relates to the therapy of tumors through neutralisation of CD137 or inhibition of CD137 expression of CD137 antagonising molecules. Furthermore, the present invention provides the use of CD137 or agonistic anti-CD307 ligand antibodies for the treatment of conditions characterised by overactive immune reactions.

Normal situation in late immune response Deletion of superfluous T cells



Pathologic situation in CLL: Subversion of anti-CLL immune response





Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

 without international search report and to be republished upon receipt of that report